ClinicalTrials.gg
TerminatedNCT05905783Updated Oct 15, 2025Results posted

Hidradenitis Suppurativa Study of Izokibep

A Phase 3 interventional study of Placebo and Izokibep in Hidradenitis Suppurativa, sponsored by ACELYRIN Inc.. Terminated at 98 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-15.

Sponsored by ACELYRIN Inc. · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
Per our 13Aug24 press release, we announced discontinuation of internal development in this indication. This decision was not due to safety reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
258
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 162 studies in Hidradenitis Suppurativa with a site in United States — 39 open to participants now, 56 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.

Enrollment
24th of 139
258 · median 45
Started
2023
with 12 others
Phase 3
24 of 162
3 open now
Registered
103rd of 162
by date

Among the 162 studies in Hidradenitis Suppurativa with a site in United States, this one is the 24th largest by enrollment of the 139 interventional ones that give a count, is one of 13 that started in 2023, is one of 24 in phase 3, and was the 103rd registered.

Hidradenitis Suppurativa

286 studies on the registry are indexed under Hidradenitis Suppurativa; 89 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

39 of the 162 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 63 Hidradenitis Suppurativa studies recruiting now, 35 (56%) set no upper age limit and 17 (27%) stop at 75 or younger; 13 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies in Hidradenitis Suppurativa with a site in United States, or all of them as a file.
02

Study summary

Izokibep is a small protein molecule that acts as a selective, potent inhibitor of interleukin 17A, to which it binds with high affinity. This study investigates izokibep in participants with active Hidradenitis Suppurativa (HS), including tumor necrosis factor-alpha inhibitor (TNFi) naïve participants, and those who had an inadequate response or intolerance to TNFi, or for whom TNFi is contraindicated.

03

Conditions studied

  • Hidradenitis Suppurativa
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General

  • Participant has provided signed including consenting to comply with the requirements and restrictions listed in the informed consent form (ICF) and in protocol
  • 18 years of age or older
  • No known history of active tuberculosis unless adequately treated according to World Health Organization/Center for Disease Control and Prevention therapeutic guidance and determined to be fully recovered by a tuberculosis specialist

Type of Participant and Disease Characteristics

  • Diagnosis of HS for ≥ 6 months prior to first dose of study drug
  • Hidradenitis suppurativa lesions present in ≥ 2 distinct anatomic areas, one of which is Hurley Stage II or Hurley Stage III
  • A total AN count of ≥ 5 at screening and Day 1 prior to enrollment/randomization
  • Participant must have had an inadequate response to oral antibiotics OR exhibited recurrence after discontinuation to, OR demonstrated intolerance to, OR have a to oral antibiotics for treatment of their HS
  • Must agree to use daily or a minimum of 3 days a week over-the-counter topical antiseptics
  • Participant must be willing to complete a daily skin pain diary

Exclusion criteria

Exclusion Criteria:

Medical Conditions

  • Draining fistula count of > 20
  • Outpatient surgery ≤ 8 weeks prior or inpatient surgery ≤ 12 weeks prior to enrollment/randomization
  • Other active skin disease or condition that could interfere with study assessments
  • History of active inflammatory bowel disease (IBD) OR symptoms within the last year that may be suggestive of IBD
  • Chronic pain not associated with HS
  • Uncontrolled, system disease
  • History of demyelinating disease or neurological symptoms suggestive of demyelinating disease
  • within 5 years
  • The participant is at risk of self-harm or harm to others
  • Active infection or history of certain infections
  • Tuberculosis or fungal infection seen on available chest x-ray taken within 3 months prior to first dose of study drug or at screening (Exception: documented evidence of completed treatment and clinically resolved)
  • Known history of (HIV)

Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
258 participants (actual)

Study arms

  • Experimental
    Group 1

    Participants will receive placebo as a subcutaneous (SC) injection every week (QW) from Day 1 to Week 15. Participants will then receive izokibep as a SC injection QW from Week 16 to Week 51.

    Drug: Placebo · Drug: Izokibep

  • Experimental
    Group 2

    Participants will receive izokibep QW from Day 1 to Week 51.

    Drug: Izokibep

Interventions

  • DrugPlacebo

    Solution for injection

  • Solution for injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 12

    The percentage of participants achieving HiSCR75 was defined as meeting all 3 criteria below: * (\[abscess and inflammatory nodule (AN) count at baseline - AN count at current visit\] / AN count at baseline) × 100% ≥ 75% * Abscess count at baseline ≥ abscess count at the current visit * Draining fistula count at baseline ≥ draining fistula count at the current visit. HiSCR75 was evaluated using nonresponse imputation (NRI) and multiple imputation (MI) methods.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants Achieving HiSCR90 at Week 12

    The percentage of participants achieving HiSCR90 was defined as meeting all 3 criteria below: * (\[AN count at baseline - AN count at current visit\] / AN count at baseline) × 100% ≥ 90% * Abscess count at baseline ≥ abscess count at the current visit * Draining fistula count at baseline ≥ draining fistula count at the current visit. HiSCR90 was evaluated using nonresponse imputation (NRI) and multiple imputation (MI) methods.

    Time frame: Week 12

  2. Percentage of Participants Achieving HiSCR100 at Week 12

    The percentage of participants achieving HiSCR100 was defined as meeting all 3 criteria below: * (\[AN count at baseline - AN count at current visit\] / AN count at baseline) × 100% = 100% * Abscess count at baseline ≥ abscess count at the current visit * Draining fistula count at baseline ≥ draining fistula count at the current visit. HiSCR100 was evaluated using nonresponse imputation (NRI) and multiple imputation (MI) methods.

    Time frame: Week 12

  3. Percentage of Participants Achieving HiSCR50 at Week 12

    The percentage of participants achieving HiSCR50 was defined as meeting all 3 criteria below: * \[(AN count at baseline - AN count at current visit) / AN count at baseline\] × 100% ≥ 50% * Abscess count at baseline ≥ abscess count at the current visit * Draining fistula count at baseline ≥ draining fistula count at the current visit. HiSCR50 was evaluated using nonresponse imputation (NRI) and multiple imputation (MI) methods.

    Time frame: Week 12

  4. Percentage of Participants Who Experienced One or More (≥ 1) Disease Flare at Week 12

    HS flares were defined as ≥ 25% increase in AN count with a minimum increase of 2 AN relative to baseline, i.e. participants must meet all the following criteria: * (AN count at current visit- AN count at baseline) / AN count at baseline ×100% ≥ 25% * AN count at current visit- AN count at baseline ≥ 2. Participants who received antibiotic therapy that could affect HS were imputed as non-response (NRI). Other participants with missing data were imputed with multiple imputation.

    Time frame: Up to Week 12

  5. Change From Baseline in Dermatology Life Quality Index (DLQI)

    DLQI included 10 items arranged in 6 categories: symptoms and feelings, daily activity, leisure, work or study, interpersonal relationships, and treatment. The total score could range from 0 (no impact to life quality) to 30 (maximum impact).

    Time frame: Baseline and Week 12

  6. Percentage of Participants With Baseline Hurley Stage II Who Achieved AN Count of 0, 1, or 2 at Week 12

    Calculated as observed values of 0, 1, or 2 for AN count (abscess count + inflammatory nodule count). AN count of 0, 1, or 2 was evaluated using nonresponse imputation (NRI) and multiple imputation (MI) methods.

    Time frame: Week 12

  7. Percentage of Participants With Baseline NRS ≥ 4 Achieving at Least 3-point Reduction at Week 12 in Numeric Rating Scale (NRS) Patient Global Assessment of Skin Pain at Its Worst

    NRS in Patient Global Assessment of Skin Pain ranged from 0 (no skin pain) to 10 (skin pain bad as you can imagine). The skin pain score at each visit was calculated using average of daily scores among the 7 days up to and including the day of visit, with a minimum of 4 days (consecutive or non-consecutive) with scores required. Reduction in NRS was evaluated using nonresponse imputation (NRI) and multiple imputation (MI) methods.

    Time frame: Week 12

  8. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious AEs (SAEs) and Adverse Event of Special Interest (AESIs) in Period 1

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. The following events of special interest were monitored in this study: candida infection; inflammatory bowel disease (IBD); suicidal ideation; malignancies; major adverse cardiovascular and cerebrovascular events; tuberculosis; infections; cytopenias and systemic hypersensitivity reactions. Clinically significant changes in vital signs and laboratory tests recorded after treatment administration were documented as TEAEs.

    Time frame: Up to Week 16

  9. Number of Participants With TEAEs, SAEs and AESIs in Period 2

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. The following events of special interest were monitored in this study: candida infection; IBD; suicidal ideation; malignancies; major adverse cardiovascular and cerebrovascular events; tuberculosis; infections; cytopenias and systemic hypersensitivity reactions. Clinically significant changes in vital signs and laboratory tests recorded after treatment administration were documented as TEAEs.

    Time frame: From Week 16 to follow-up, Week 59

07

Results

Posted Oct 15, 2025

Participant flow

A total of 258 participants were enrolled in Canada, France, Germany, Japan, Poland, Spain and the United States from June 2023 to January 2025. Participants were randomized to receive izokibep or placebo once weekly (QW) until Week 15 (Period 1). Then, all participants received izokibep QW from Week 16 until Week 51 (Period 2). The Sponsor decided to terminate the study early after all participants completed (or discontinued) treatment at Week 32.

Participant flow — Overall Study
MilestonePlacebo-Izokibep 160 mg QWIzokibep 160 mg QW
Started129129
Completed period 1109103
Completed199
Not completed110120
Withdrew: Lost to follow-up1218
Withdrew: Withdrawal by subject2937
Withdrew: Decision by sponsor6965

Outcome measures

PrimaryPercentage of Participants Achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 12

The percentage of participants achieving HiSCR75 was defined as meeting all 3 criteria below: * (\[abscess and inflammatory nodule (AN) count at baseline - AN count at current visit\] / AN count at baseline) × 100% ≥ 75% * Abscess count at baseline ≥ abscess count at the current visit * Draining fistula count at baseline ≥ draining fistula count at the current visit. HiSCR75 was evaluated using nonresponse imputation (NRI) and multiple imputation (MI) methods.

Time frame:
Week 12
Reported as:
Mean · percentage of participants
Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 12
percentage of participantsPlacebo-Izokibep 160 mg QWIzokibep 160 mg QW
Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 1220.3 (13.1 to 27.6)32.6 (24.3 to 40.9)
Statistical analysis
  • Placebo-Izokibep 160 mg QW vs Izokibep 160 mg QW · Cochran-Mantel-Haenszel · p = 0.0183 · Risk difference (rd): 13.0 · 95% CI 2.2 to 23.7
SecondaryPercentage of Participants Achieving HiSCR90 at Week 12

The percentage of participants achieving HiSCR90 was defined as meeting all 3 criteria below: * (\[AN count at baseline - AN count at current visit\] / AN count at baseline) × 100% ≥ 90% * Abscess count at baseline ≥ abscess count at the current visit * Draining fistula count at baseline ≥ draining fistula count at the current visit. HiSCR90 was evaluated using nonresponse imputation (NRI) and multiple imputation (MI) methods.

Time frame:
Week 12
Reported as:
Mean · percentage of participants
Percentage of Participants Achieving HiSCR90 at Week 12
percentage of participantsPlacebo-Izokibep 160 mg QWIzokibep 160 mg QW
Percentage of Participants Achieving HiSCR90 at Week 129.2 (3.8 to 14.5)24.3 (16.7 to 31.9)
Statistical analysis
  • Placebo-Izokibep 160 mg QW vs Izokibep 160 mg QW · Cochran-Mantel-Haenszel · p = 0.0007 · Risk difference (rd): 15.8 · 95% CI 6.7 to 25.0
SecondaryPercentage of Participants Achieving HiSCR100 at Week 12

The percentage of participants achieving HiSCR100 was defined as meeting all 3 criteria below: * (\[AN count at baseline - AN count at current visit\] / AN count at baseline) × 100% = 100% * Abscess count at baseline ≥ abscess count at the current visit * Draining fistula count at baseline ≥ draining fistula count at the current visit. HiSCR100 was evaluated using nonresponse imputation (NRI) and multiple imputation (MI) methods.

Time frame:
Week 12
Reported as:
Mean · percentage of participants
Percentage of Participants Achieving HiSCR100 at Week 12
percentage of participantsPlacebo-Izokibep 160 mg QWIzokibep 160 mg QW
Percentage of Participants Achieving HiSCR100 at Week 127.3 (2.5 to 12.2)21.4 (14.2 to 28.7)
Statistical analysis
  • Placebo-Izokibep 160 mg QW vs Izokibep 160 mg QW · Cochran-Mantel-Haenszel · p = 0.0008 · Risk difference (rd): 14.7 · 95% CI 6.1 to 23.4
SecondaryPercentage of Participants Achieving HiSCR50 at Week 12

The percentage of participants achieving HiSCR50 was defined as meeting all 3 criteria below: * \[(AN count at baseline - AN count at current visit) / AN count at baseline\] × 100% ≥ 50% * Abscess count at baseline ≥ abscess count at the current visit * Draining fistula count at baseline ≥ draining fistula count at the current visit. HiSCR50 was evaluated using nonresponse imputation (NRI) and multiple imputation (MI) methods.

Time frame:
Week 12
Reported as:
Mean · percentage of participants
Percentage of Participants Achieving HiSCR50 at Week 12
percentage of participantsPlacebo-Izokibep 160 mg QWIzokibep 160 mg QW
Percentage of Participants Achieving HiSCR50 at Week 1236.5 (27.8 to 45.2)47.9 (39.0 to 56.8)
Statistical analysis
  • Placebo-Izokibep 160 mg QW vs Izokibep 160 mg QW · Cochran-Mantel-Haenszel · p = 0.0462 · Risk difference (rd): 12.3 · 95% CI 0.2 to 24.3
SecondaryPercentage of Participants Who Experienced One or More (≥ 1) Disease Flare at Week 12

HS flares were defined as ≥ 25% increase in AN count with a minimum increase of 2 AN relative to baseline, i.e. participants must meet all the following criteria: * (AN count at current visit- AN count at baseline) / AN count at baseline ×100% ≥ 25% * AN count at current visit- AN count at baseline ≥ 2. Participants who received antibiotic therapy that could affect HS were imputed as non-response (NRI). Other participants with missing data were imputed with multiple imputation.

Time frame:
Up to Week 12
Reported as:
Mean · percentage of participants
Percentage of Participants Who Experienced One or More (≥ 1) Disease Flare at Week 12
percentage of participantsPlacebo-Izokibep 160 mg QWIzokibep 160 mg QW
Percentage of Participants Who Experienced One or More (≥ 1) Disease Flare at Week 1231.1 (22.9 to 39.3)28.3 (20.5 to 36.2)
Statistical analysis
  • Placebo-Izokibep 160 mg QW vs Izokibep 160 mg QW · Cochran-Mantel-Haenszel · p = 0.6285 · Risk difference (rd): -2.8 · 95% CI -14.3 to 8.6
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI)

DLQI included 10 items arranged in 6 categories: symptoms and feelings, daily activity, leisure, work or study, interpersonal relationships, and treatment. The total score could range from 0 (no impact to life quality) to 30 (maximum impact).

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Score on scale
Change From Baseline in Dermatology Life Quality Index (DLQI)
Score on scalePlacebo-Izokibep 160 mg QWIzokibep 160 mg QW
Change From Baseline in Dermatology Life Quality Index (DLQI)-2.71 ± 0.519-4.87 ± 0.536
Statistical analysis
  • Placebo-Izokibep 160 mg QW vs Izokibep 160 mg QW · Mixed model repeated measures (MMRM) · p = 0.0011 · Ls mean difference: -2.16 · 95% CI -3.44 to -0.88
SecondaryPercentage of Participants With Baseline Hurley Stage II Who Achieved AN Count of 0, 1, or 2 at Week 12

Calculated as observed values of 0, 1, or 2 for AN count (abscess count + inflammatory nodule count). AN count of 0, 1, or 2 was evaluated using nonresponse imputation (NRI) and multiple imputation (MI) methods.

Time frame:
Week 12
Reported as:
Mean · percentage of participants
Percentage of Participants With Baseline Hurley Stage II Who Achieved AN Count of 0, 1, or 2 at Week 12
percentage of participantsPlacebo-Izokibep 160 mg QWIzokibep 160 mg QW
Percentage of Participants With Baseline Hurley Stage II Who Achieved AN Count of 0, 1, or 2 at Week 1225.0 (15.2 to 34.8)49.5 (38.1 to 61.0)
Statistical analysis
  • Placebo-Izokibep 160 mg QW vs Izokibep 160 mg QW · Cochran-Mantel-Haenszel · p = 0.0013 · Risk difference (rd): 24.6 · 95% CI 9.6 to 39.7
SecondaryPercentage of Participants With Baseline NRS ≥ 4 Achieving at Least 3-point Reduction at Week 12 in Numeric Rating Scale (NRS) Patient Global Assessment of Skin Pain at Its Worst

NRS in Patient Global Assessment of Skin Pain ranged from 0 (no skin pain) to 10 (skin pain bad as you can imagine). The skin pain score at each visit was calculated using average of daily scores among the 7 days up to and including the day of visit, with a minimum of 4 days (consecutive or non-consecutive) with scores required. Reduction in NRS was evaluated using nonresponse imputation (NRI) and multiple imputation (MI) methods.

Time frame:
Week 12
Reported as:
Mean · Percentage of participants
Percentage of Participants With Baseline NRS ≥ 4 Achieving at Least 3-point Reduction at Week 12 in Numeric Rating Scale (NRS) Patient Global Assessment of Skin Pain at Its Worst
Percentage of participantsPlacebo-Izokibep 160 mg QWIzokibep 160 mg QW
Percentage of Participants With Baseline NRS ≥ 4 Achieving at Least 3-point Reduction at Week 12 in Numeric Rating Scale (NRS) Patient Global Assessment of Skin Pain at Its Worst17.2 (8.4 to 25.9)33.5 (22.1 to 44.8)
Statistical analysis
  • Placebo-Izokibep 160 mg QW vs Izokibep 160 mg QW · Cochran-Mantel-Haenszel · p = 0.0245 · Risk difference (rd): 16.3 · 95% CI 2.1 to 30.6
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Serious AEs (SAEs) and Adverse Event of Special Interest (AESIs) in Period 1

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. The following events of special interest were monitored in this study: candida infection; inflammatory bowel disease (IBD); suicidal ideation; malignancies; major adverse cardiovascular and cerebrovascular events; tuberculosis; infections; cytopenias and systemic hypersensitivity reactions. Clinically significant changes in vital signs and laboratory tests recorded after treatment administration were documented as TEAEs.

Time frame:
Up to Week 16
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious AEs (SAEs) and Adverse Event of Special Interest (AESIs) in Period 1
ParticipantsPlacebo-Izokibep 160 mg QWIzokibep 160 mg QW
TEAEs76107
SAEs51
AESIs30
SecondaryNumber of Participants With TEAEs, SAEs and AESIs in Period 2

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. The following events of special interest were monitored in this study: candida infection; IBD; suicidal ideation; malignancies; major adverse cardiovascular and cerebrovascular events; tuberculosis; infections; cytopenias and systemic hypersensitivity reactions. Clinically significant changes in vital signs and laboratory tests recorded after treatment administration were documented as TEAEs.

Time frame:
From Week 16 to follow-up, Week 59
Reported as:
Count of participants · Participants
Number of Participants With TEAEs, SAEs and AESIs in Period 2
ParticipantsPlacebo-Izokibep 160 mg QWIzokibep 160 mg QW
TEAEs8766
SAEs34
AESIs51

Adverse events

Collected over From Screening (Day -28) to Follow-up (Week 59), up to approximately 63 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo QW - Izokibep 160 mg QW: Period 10/129 (0%)5/129 (3.9%)35/129 (27.1%)
Izokibep 160 mg QW: Period 10/129 (0%)1/129 (0.8%)93/129 (72.1%)
Placebo QW - Izokibep 160 mg QW: Period 20/109 (0%)3/109 (2.8%)69/109 (63.3%)
Izokibep 160 mg QW: Period 20/100 (0%)4/100 (4%)40/100 (40%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPlacebo QW - Izokibep 160 mg QW: Period 1Izokibep 160 mg QW: Period 1Placebo QW - Izokibep 160 mg QW: Period 2Izokibep 160 mg QW: Period 2
HidradenitisSkin and subcutaneous tissue disorders1/1290/1290/1091/100
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/1290/1290/1091/100
Spinal stenosisMusculoskeletal and connective tissue disorders0/1290/1290/1091/100
Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1290/1290/1091/100
Eye disorderEye disorders0/1290/1290/1091/100
Hepatic enzyme increasedInvestigations1/1290/1291/1090/100
Transitional cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1290/1291/1090/100
CellulitisInfections and infestations0/1290/1291/1090/100
Pelvic fractureInjury, poisoning and procedural complications1/1290/1290/1090/100
Post procedural complicationInjury, poisoning and procedural complications1/1290/1290/1090/100
Most frequent other events
Most frequent other events
EventPlacebo QW - Izokibep 160 mg QW: Period 1Izokibep 160 mg QW: Period 1Placebo QW - Izokibep 160 mg QW: Period 2Izokibep 160 mg QW: Period 2
Injection site reactionGeneral disorders10/12986/12966/10934/100
HeadacheNervous system disorders16/12914/1292/1095/100
NasopharyngitisInfections and infestations9/12911/1295/1098/100
FatigueGeneral disorders3/1297/1290/1092/100
Upper respiratory tract infectionInfections and infestations5/1297/1295/1094/100
DiarrhoeaGastrointestinal disorders2/1297/1290/1090/100

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Placebo-Izokibep 160 mg QWIzokibep 160 mg QWTotal
<=18 years000
Between 18 and 65 years125127252
>=65 years426
Age, Continuous
Age, Continuous(years)Placebo-Izokibep 160 mg QWIzokibep 160 mg QWTotal
Mean37.4 ± 12.8537.1 ± 11.8937.3 ± 12.35
Sex: Female, Male
Sex: Female, Male(Participants)Placebo-Izokibep 160 mg QWIzokibep 160 mg QWTotal
Female8989178
Male404080
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo-Izokibep 160 mg QWIzokibep 160 mg QWTotal
Hispanic or Latino181230
Not Hispanic or Latino108115223
Unknown or Not Reported325
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo-Izokibep 160 mg QWIzokibep 160 mg QWTotal
American Indian or Alaska Native033
Asian10818
Native Hawaiian or Other Pacific Islander011
Black or African American282149
White9091181
More than one race000
Other156
08

Study locations

98 sites
  • Clinical Research Site
    Birmingham, Alabama 35233, United States
  • Clinical Research Site
    Scottsdale, Arizona 85255, United States
  • Clinical Research Site
    Scottsdale, Arizona 85260, United States
  • Clinical Research Site
    Fayetteville, Arkansas 72703, United States
  • Clinical Research Site
    Encino, California 91436, United States
  • Clinical Research Site
    Fountain Valley, California 92708, United States
  • Clinical Research Site
    Fremont, California 94538, United States
  • Clinical Research Site
    Los Angeles, California 90045, United States
  • Clinical Research Site
    Santa Monica, California 90404, United States
  • Clinical Research Site
    Boca Raton, Florida 33486, United States
  • Clinical Research Site
    Brandon, Florida 33511, United States
  • Clinical Research Site
    Coral Gables, Florida 33134, United States
  • Clinical Research Site
    Hollywood, Florida 33021, United States
  • Clinical Research Site
    Tampa, Florida 33607, United States
  • Clinical Research Site
    Tampa, Florida 33613, United States
  • Clinical Research Site
    Atlanta, Georgia 30315, United States
  • Clinical Research Site
    Sandy Springs, Georgia 30328, United States
  • Clinical Research Site
    Savannah, Georgia 31419, United States
  • Clinical Research Site
    Springfield, Illinois 62702, United States
  • Clinical Research Site
    Indianapolis, Indiana 46250, United States
  • Clinical Research Site
    Plainfield, Indiana 46168, United States
  • Clinical Research Site
    Topeka, Kansas 66614, United States
  • Clinical Research Site
    Murray, Kentucky 42071, United States
  • Clinical Research Site
    Baton Rouge, Louisiana 70808, United States
  • Clinical Research Site
    Baton Rouge, Louisiana 70809, United States
  • Clinical Research Site
    New Orleans, Louisiana 70115, United States
  • Clinical Research Site
    Largo, Maryland 20774, United States
  • Clinical Research Site
    Boston, Massachusetts 02215, United States
  • Clinical Research Site
    Canton, Michigan 48187, United States
  • Clinical Research Site
    Troy, Michigan 48084, United States
  • Clinical Research Site
    Lebanon, New Hampshire 03766, United States
  • Clinical Research Site
    New York, New York 10128, United States
  • Clinical Research Site
    Charlotte, North Carolina 28277, United States
  • Clinical Research Site
    Boardman, Ohio 44512, United States
  • Clinical Research Site
    Mason, Ohio 45040, United States
  • Clinical Research Site
    Springfield, Ohio 45505, United States
  • Clinical Research Site
    Portland, Oregon 97223, United States
  • Clinical Research Site
    Hershey, Pennsylvania 17033, United States
  • Clinical Research Site
    Pittsburgh, Pennsylvania 15213, United States
  • Clinical Research Site
    Sugarloaf, Pennsylvania 18249, United States
  • Clinical Research Site
    Thompson's Station, Tennessee 37179, United States
  • Clinical Research Site
    Arlington, Texas 76011, United States
  • Clinical Research Site
    Frisco, Texas 75034, United States
  • Clinical Research Site
    Pflugerville, Texas 78660, United States
  • Clinical Research Site
    San Antonio, Texas 78218, United States
  • Clinical Research Site
    The Woodlands, Texas 77380, United States
  • Clinical Research Site
    Webster, Texas 77598, United States
  • Clinical Research Site
    Springville, Utah 84663, United States
  • Clinical Research Site
    West Jordan, Utah 84088, United States
  • Clinical Research Site
    Charlottesville, Virginia 22908, United States
  • Clinical Research Site
    Edmonton, Alberta T6G1C3, Canada
  • Clinical Research Site
    Edmonton, Alberta T6H4J8, Canada
  • Clinical Research Site
    Winnipeg, Manitoba R3M3Z4, Canada
  • Clinical Research Site
    North Bay, Ontario P1B 3Z7, Canada
  • Clinical Research Site
    Peterborough, Ontario K9J5K2, Canada
  • Clinical Research Site
    Toronto, Ontario M2N3A6, Canada
  • Clinical Research Site
    Toronto, Ontario M4W2N4, Canada
  • Clinical Research Site
    Toronto, Ontario M5A3R6, Canada
  • Clinical Research Site
    Waterloo, Ontario N2J1C4, Canada
  • Clinical Research Site
    Saskatoon, Saskatchewan S7K2C1, Canada
  • Clinical Research Site
    Dijon, Bourgogne-Franche-Comté 21000, France
  • Clinical Research Site
    Montpellier, Occitanie 34090, France
  • Clinical Research Site
    Nantes, Pays de la Loire Region 44000, France
  • Clinical Research Site
    Toulon, 83000, France
  • Clinical Research Site
    Darmstadt, Hesse 64283, Germany
  • Clinical Research Site
    Bad Bentheim, Lower Saxony 48455, Germany
  • Clinical Research Site
    Mainz, Rhineland-Palatinate 55128, Germany
  • Clinical Research Site
    Leipzig, Saxony 04103, Germany
  • Clinical Research Site
    Kiel, Schleswig-Holstein 24148, Germany
  • Clinical Research Site
    Debrecen, Hajdú-Bihar 4032, Hungary
  • Clinical Research Site
    Zalaegerszeg, Zala County 8900, Hungary
  • Clinical Research Site
    Budapest, 1036, Hungary
  • Clinical Research Site
    Fukuoka, Fukoka Prefecture 814-0180, Japan
  • Clinical Research Site
    Kitakyushu, Fukuoka 807-8555, Japan
  • Clinical Research Site
    Obihiro, Hokkaido Prefecture 080-0013, Japan
  • Clinical Research Site
    Sapporo, Hokkaido Prefecture 060-0063, Japan
  • Clinical Research Site
    Kawasaki, Kanagawa 216-8511, Japan
  • Clinical Research Site
    Yokohama, Kanagawa 236-0004, Japan
  • Clinical Research Site
    Kyoto, Kyoto 602-8566, Japan
  • Clinical Research Site
    Osaka, Osaka 589-8511, Japan
  • Clinical Research Site
    Shinjuku-Ku, Tokyo 160-0023, Japan
  • Clinical Research Site
    tabashi City, Tokyo 173-8610, Japan
  • Clinical Research Site
    Nishinomiya, 663-8186, Japan
  • Clinical Research Site
    Krakow, Lesser Poland Voivodeship 30-001, Poland
  • Clinical Research Site
    Krakow, Lesser Poland Voivodeship 90-436, Poland
  • Clinical Research Site
    Wroclaw, Lower Silesian Voivodeship 50-566, Poland
  • Clinical Research Site
    Wroclaw, Lower Silesian Voivodeship 51-318, Poland
  • Clinical Research Site
    Lublin, Lublin Voivodeship 20-573, Poland
  • Clinical Research Site
    Katowice, Silesian Voivodeship 40-611, Poland
  • Clinical Research Site
    Ożarowice, Silesian Voivodeship 42-624, Poland
  • Clinical Research Site
    Sosnowiec, Silesian Voivodeship 41-218, Poland
  • Clinical Research Site
    Lodz, Łódź Voivodeship 90-265, Poland
  • Clinical Research Site
    Seville, Andalusia 41009, Spain
  • Clinical Research Site
    Palma de Mallorca, Balearic Islands 07120, Spain
  • Clinical Research Site
    Badalona, Catalonia 08916, Spain
  • Clinical Research Site
    Barcelona, Catalonia 08041, Spain
  • Clinical Research Site
    Manises, Valencia 46940, Spain
  • Clinical Research Site
    Madrid, 28031, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Jul 2024, 13 months.

Results were first posted in Oct 2025, 1 year 2 months after primary completion. A results delay was requested in Apr 2025.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2023
First posted
Jun 15, 2023
StartActual
Jun 22, 2023
Primary completionActual
Jul 24, 2024
CompletionActual
Jan 27, 2025
Results delay requested
Apr 3, 2025
Results first posted
Oct 15, 2025
Last update
Oct 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05905783
Lead sponsor
ACELYRIN Inc.
Responsible party
Sponsor
First posted
Jun 15, 2023
Start date
Jun 22, 2023
Primary completion
Jul 24, 2024
Completion
Jan 27, 2025
Results posted
Oct 15, 2025
Last update
Oct 15, 2025

Study contacts

Shephard Mpofu
study director · ACELYRIN Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Izokibep

Start the discussion